Skip to main content
NAVCO Pharmaceuticals logo

NAVCO Pharmaceuticals — Investor Relations & Filings

Ticker · NAV ISIN · CA63942R1091 LEI · 8945003WKDH61M8UB963 TSXV Manufacturing
Open in API
Filings indexed 199 across all filing types
Latest filing 2023-02-27 Interim / Quarterly Rep…
Country CA Canada
Listing TSXV NAV

About NAVCO Pharmaceuticals

https://www.navcopharma.com/

NAVCO Pharmaceuticals is a biotechnology company specializing in the research, development, and commercialization of nanotechnology products and materials. The company utilizes proprietary Computerized Nano-meter Algorithms to create innovative solutions for anti-viral, anti-fungal, and anti-bacterial treatments. NAVCO focuses on developing supplemental and therapeutic consumer health and wellness products. A key offering is the BioActive™ line, which includes non-toxic, non-flammable, and alcohol-free hand cleansers, creams, and surface disinfectants designed to provide extended protection against germs and microorganisms. These nanotechnology products are marketed across various sectors, including medicine and textiles, providing next-generation protection solutions for multiple industries.

Recent filings

Filing Released Lang Actions
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Management’s Discussion and Analysis' (MD&A) for the six months ended December 31, 2022, which is a detailed explanation by management of the company's financial results, business trends, liquidity, capital resources, and outlook for a period shorter than a full fiscal year. It contains substantive financial data and analysis, including net loss, revenues, working capital, and quarterly results. The document references condensed interim financial statements and is dated February 27, 2023. The length is about 15,000 characters, indicating it is a full report rather than a brief announcement. The MD&A is a standard component of interim or quarterly reports. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-02-27 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Financial Statements' for BMGB Capital Corp. for the three and six months ended December 31, 2022. It contains detailed financial statements including Statements of Financial Position, Operations and Comprehensive Loss, Changes in Shareholders' Equity, and Cash Flows, all marked as unaudited and expressed in Canadian dollars. The notes discuss accounting policies and going concern assumptions. The presence of comprehensive financial data for a period shorter than a full fiscal year, specifically quarterly and half-year data, and the use of the term 'interim' clearly indicate this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial statements and analysis, not just an announcement or certification. Therefore, the correct classification is 'IR' (Interim / Quarterly Report). H1 2023
2023-02-27 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that BMGB Capital Corp. has filed a filing statement dated November 28, 2022, related to a qualifying transaction under TSX Venture Exchange Policy 2.4 for Capital Pool Companies. The text describes the transaction details, share exchange agreement, private placement, and regulatory approvals required. It does not contain actual financial statements or detailed financial analysis but rather announces the filing of a statement and provides background and forward-looking information. The document length is 8270 characters, which is relatively short and consistent with an announcement rather than a full report. The key phrase 'has filed a filing statement' and references to the document being available on SEDAR indicate this is an announcement of a filing rather than the filing statement itself. Therefore, this document fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about the filing of a statement related to a qualifying transaction, without substantive financial data or report content.
2022-12-01 English
Other.pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed offering document for NBC Booster Note Securities, including terms, investment highlights, risk factors, and pricing supplement references. It is a prospectus supplement or pricing supplement related to a note securities offering, describing the terms and conditions of the securities, investment suitability, risk disclosures, and other offering details. It is not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual offering document. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including prospectuses and offering documents for securities issuance.
2022-12-01 English
Filing statement - English.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Filing Statement' and references a 'Qualifying Transaction pursuant to Policy 2.4 of the TSX Venture Exchange.' It includes detailed sections such as corporate structure, financial information, management discussion and analysis, share capital, executive compensation, legal proceedings, and material contracts. The content is comprehensive and covers a proposed transaction, financial data, and corporate governance aspects. This type of document is typical for a filing statement related to a qualifying transaction on a venture exchange, which is a detailed disclosure document rather than a simple announcement or presentation. It does not fit the categories of Annual Report, Interim Report, Earnings Release, or other more common financial reports. Instead, it aligns with a Regulatory Filing (RNS) as it is a formal disclosure document filed with a securities regulatory authority and the exchange, providing detailed information about a transaction and the company. The length (15,000 characters) and detailed content confirm it is not a brief announcement or a certification. Therefore, the best classification is Regulatory Filings (RNS).
2022-12-01 English
Other.pdf
Regulatory Filings Classification · 95% confidence The document is a letter from a Chartered Professional Accountant addressed to the TSX Venture Exchange. It references a filing statement dated November 28, 2022, related to a qualifying transaction under Policy 2.4 of the TSX Venture Exchange. The letter provides consent for the use of the auditor's report dated February 14, 2022, on financial statements of Navco Pharmaceuticals Limited. The letter explicitly states it is not an audit or review of the filing statement itself but a consent letter for the use of the auditor's report in an offering document. The document is short (1994 characters) and serves as an auditor's consent letter rather than containing financial statements or substantive financial data. According to the CERTIFICATION RULE, such a document should be classified as a Regulatory Filing (RNS) because it is an officer certification/attestation related to a filing statement and does not contain the financial report itself.
2022-12-01 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.